Dear Colleagues,

Cancer is one of the leading causes of death worldwide and represents a significant public health challenge. It has been estimated that there are over 19 million new cases of cancer diagnosed worldwide each year. These numbers continue to rise due to population growth, aging, and changes in lifestyle. It can be a lethal disease due to its recurrence and metastasis, particularly if not detected and treated in its early stages. Cancer treatment involves surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, or a combination of these approaches. Currently, with the success of immune checkpoint inhibition treatment, research on tumor vaccines, which are an important component of tumor immunotherapy, has also become a hot topic in the field of cancer treatment research and has become the focal point of attention for immunologists, oncologists and cancer pharmacologists in the field of tumor immunotherapy.

In order to better understand and keep up with the latest scientific advancements and development trends in the field of tumor vaccine research, this Special Issue is focused on the recent scientific and technical progress made in this field. Based on your extensive knowledge and experience, we are pleased to invite you to contribute with original research articles and reviews about cancer vaccines. Research areas may include (but are not limited to) the following: (i) the design and development and anti-tumor prophylactic and therapeutic effects of tumor vaccine, (ii) the mechanisms of the vaccine-induced anti-tumor immune response, (iii) the modulation of the tumor immune microenvironment using tumor vaccines, (iv) combination therapy of tumor vaccines with other therapies, and (v) recent advances in novel tumor prophylactic and therapeutic vaccines. 

We look forward to receiving your contributions.

Prof. Dr. Haihong Zhang
Prof. Dr. Xianghui Yu
Prof. Dr. Yongge Wu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• tumor vaccine
• tumor immunotherapy
• tumor combination therapy
• tumor antigen
• DC targeting
• antigen presentation
• tumor RNA vaccine
• tumor neoantigen
• the tumor-immune microenvironment